{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T20:58:57Z","timestamp":1773867537529,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"10","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1007\/s12325-014-0155-3","type":"journal-article","created":{"date-parts":[[2014,9,26]],"date-time":"2014-09-26T02:35:44Z","timestamp":1411698944000},"page":"1059-1071","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Ocular Itch Relief with Alcaftadine 0.25% Versus Olopatadine 0.2% in Allergic Conjunctivitis: Pooled Analysis of Two Multicenter Randomized Clinical Trials"],"prefix":"10.1007","volume":"31","author":[{"given":"Eugene B.","family":"McLaurin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas P.","family":"Marsico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacey L.","family":"Ackerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph B.","family":"Ciolino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia M.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Villanueva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Hollander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,9,27]]},"reference":[{"key":"155_CR1","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0181-5512(06)73857-8","volume":"29","author":"B Mortemousque","year":"2006","unstructured":"Mortemousque B, Fauquert JL, Chiambaretta F, Demoly P, Helleboid L, Creuzot-Garcher C, et al. Conjunctival provocation test: recommendations. J Fr Ophtalmol. 2006;29:837\u201346.","journal-title":"J Fr Ophtalmol"},{"key":"155_CR2","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1111\/all.12009","volume":"67","author":"A Leonardi","year":"2012","unstructured":"Leonardi A, Bogacka E, Fauquert JL, Kowalski ML, Groblewska A, Jedrzejczak-Czechowicz M, et al. Ocular allergy: recognizing and diagnosing hypersensitivity disorders of the ocular surface. Allergy. 2012;67:1327\u201337.","journal-title":"Allergy"},{"key":"155_CR3","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/ACI.0b013e32834a9676","volume":"11","author":"N Rosario","year":"2011","unstructured":"Rosario N, Bielory L. Epidemiology of allergic conjunctivitis. Curr Opin Allergy Clin Immunol. 2011;11:471\u20136.","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"155_CR4","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2500\/aap.2007.28.3013","volume":"28","author":"MS Blaiss","year":"2007","unstructured":"Blaiss MS. Allergic rhinoconjunctivitis: burden of disease. Allergy Asthma Proc. 2007;28:393\u20137.","journal-title":"Allergy Asthma Proc."},{"key":"155_CR5","doi-asserted-by":"crossref","first-page":"778.e6","DOI":"10.1016\/j.jaci.2010.06.050","volume":"126","author":"K Singh","year":"2010","unstructured":"Singh K, Axelrod S, Bielory L. The epidemiology of ocular and nasal allergy in the United States, 1988\u20131994. J Allergy Clin Immunol. 2010;126:778\u201383.e6.","journal-title":"J Allergy Clin Immunol."},{"key":"155_CR6","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1399-3038.2007.00601.x","volume":"19","author":"B Bj\u00f6rksten","year":"2008","unstructured":"Bj\u00f6rksten B, Clayton T, Ellwood P, Stewart A, Strachan D, ISAAC Phase III Study Group. Worldwide time trends for symptoms of rhinitis and conjunctivitis: phase III of the International Study of Asthma and Allergies in Childhood. Pediatr Allergy Immunol. 2008;19:110\u201324.","journal-title":"Pediatr Allergy Immunol"},{"key":"155_CR7","first-page":"108","volume-title":"Allergic diseases of the eye","author":"L Collum","year":"2000","unstructured":"Collum L, Kilmartin DJ. Acute Allergic Conjunctivitis. In: Abelson MB, editor. Allergic diseases of the eye. Philadelphia: W.B. Saunders Co; 2000. p. 108\u201332."},{"key":"155_CR8","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/ACI.0b013e3282ef8674","volume":"7","author":"A Leonardi","year":"2007","unstructured":"Leonardi A, De Dominicis C, Motterle L. Immunopathogenesis of ocular allergy: a schematic approach to different clinical entities. Curr Opin Allergy Clin Immunol. 2007;7:429\u201335.","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"155_CR9","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jaci.2004.10.042","volume":"115","author":"SJ Ono","year":"2005","unstructured":"Ono SJ, Abelson MB. Allergic conjunctivitis: update on pathophysiology and prospects for future treatment. J Allergy Clin Immunol. 2005;115:118\u201322.","journal-title":"J Allergy Clin Immunol."},{"key":"155_CR10","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1001\/archopht.1981.03930010304018","volume":"99","author":"MB Abelson","year":"1981","unstructured":"Abelson MB, Udell IJ. H2-receptors in the human ocular surface. Arch Ophthalmol. 1981;99:302\u20134.","journal-title":"Arch Ophthalmol"},{"key":"155_CR11","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/01.all.0000183113.63311.11","volume":"5","author":"L Bielory","year":"2005","unstructured":"Bielory L, Ghafoor S. Histamine receptors and the conjunctiva. Curr Opin Allergy Clin Immunol. 2005;5:437\u201340.","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"155_CR12","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ejphar.2009.02.035","volume":"608","author":"Y Nakano","year":"2009","unstructured":"Nakano Y, Takahashi Y, Ono R, Kurata Y, Kagawa Y, Kamei C. Role of histamine H4 receptor in allergic conjunctivitis in mice. Eur J Pharmacol. 2009;608:71\u20135.","journal-title":"Eur J Pharmacol"},{"key":"155_CR13","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00011-009-8245-4","volume":"58","author":"E Zampeli","year":"2009","unstructured":"Zampeli E, Thurmond RL, Tiligada E. The histamine H4 receptor antagonist JNJ7777120 induces increases in the histamine content of the rat conjunctiva. Inflamm Res. 2009;58:285\u201391.","journal-title":"Inflamm Res"},{"key":"155_CR14","first-page":"87","volume":"5","author":"JV Greiner","year":"2011","unstructured":"Greiner JV, Edwards-Swanson K, Ingerman A. Evaluation of alcaftadine 0.25% ophthalmic solution in acute allergic conjunctivitis at 15 minutes and 16 hours after instillation versus placebo and olopatadine 0.1%. Clin Ophthalmol. 2011;5:87\u201393.","journal-title":"Clin Ophthalmol."},{"key":"155_CR15","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1185\/03007995.2010.548797","volume":"27","author":"G Torkildsen","year":"2011","unstructured":"Torkildsen G, Shedden A. The safety and efficacy of alcaftadine 0.25% ophthalmic solution for the prevention of itching associated with allergic conjunctivitis. Curr Med Res Opin. 2011;27:623\u201331.","journal-title":"Curr Med Res Opin"},{"key":"155_CR16","unstructured":"Lastacaft\u00ae (alcaftadine ophthalmic solution) 0.25% Prescribing Information, Allergan, Inc., Irvine, CA. 2011. URL: http:\/\/www.allergan.com\/assets\/pdf\/lastacaft_pi.pdf . Accessed March 14, 2014."},{"key":"155_CR17","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1080\/02713680701736558","volume":"32","author":"MB Abelson","year":"2007","unstructured":"Abelson MB, Spangler DL, Epstein AB, Mah FS, Crampton HJ. Efficacy of once-daily olopatadine 0.2% ophthalmic solution compared to twice-daily olopatadine 0.1% ophthalmic solution for the treatment of ocular itching induced by conjunctival allergen challenge. Curr Eye Res. 2007;32:1017\u201322.","journal-title":"Curr Eye Res"},{"key":"155_CR18","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/BF02877768","volume":"24","author":"SV Scoper","year":"2007","unstructured":"Scoper SV, Berdy GJ, Lichtenstein SJ, Rubin JM, Bloomenstein M, Prouty RE, et al. Perception and quality of life associated with the use of olopatadine 0.2% (Pataday) in patients with active allergic conjunctivitis. Adv Ther. 2007;24:1221\u201332.","journal-title":"Adv Ther."},{"key":"155_CR19","unstructured":"Pataday\u00ae (olopatadine hydrochloride ophthalmic solution) 0.2% Prescribing Information, Alcon Laboratories, Inc., Fort Worth, TX. 2010. URL: http:\/\/ecatalog.alcon.com\/PI\/Pataday_us_en.pdf . Accessed March 14, 2014."},{"key":"155_CR20","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1097\/ACI.0b013e328357d3ba","volume":"12","author":"L Wade","year":"2012","unstructured":"Wade L, Bielory L, Rudner S. Ophthalmic antihistamines and H1\u2013H4 receptors. Curr Opin Allergy Clin Immunol. 2012;12:510\u20136.","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"155_CR21","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1001\/archopht.1990.01070030090035","volume":"108","author":"MB Abelson","year":"1990","unstructured":"Abelson MB, Chambers WA, Smith LM. Conjunctival allergen challenge. A clinical approach to studying allergic conjunctivitis. Arch Ophthalmol. 1990;108:84\u20138.","journal-title":"Arch Ophthalmol"},{"key":"155_CR22","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s11882-003-0100-z","volume":"3","author":"MB Abelson","year":"2003","unstructured":"Abelson MB, Loeffler O. Conjunctival allergen challenge: models in the investigation of ocular allergy. Curr Allergy Asthma Rep. 2003;3:363\u20138.","journal-title":"Curr Allergy Asthma Rep."},{"key":"155_CR23","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S1081-1206(10)62814-1","volume":"81","author":"MB Abelson","year":"1998","unstructured":"Abelson MB. Evaluation of olopatadine, a new ophthalmic antiallergic agent with dual activity, using the conjunctival allergen challenge model. Ann Allergy Asthma Immunol. 1998;81:211\u20138.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"155_CR24","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0149-2918(04)90004-5","volume":"26","author":"MB Abelson","year":"2004","unstructured":"Abelson MB, Gomes P, Crampton HJ, Schiffman RM, Bradford RR, Whitcup SM. Efficacy and tolerability of ophthalmic epinastine assessed using the conjunctival antigen challenge model in patients with a history of allergic conjunctivitis. Clin Ther. 2004;26:35\u201347.","journal-title":"Clin Ther"},{"key":"155_CR25","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1016\/j.clinthera.2009.09.001","volume":"31","author":"MB Abelson","year":"2009","unstructured":"Abelson MB, Torkildsen GL, Williams JI, Gow JA, Gomes PJ. McNamara TR; Bepotastine Besilate Ophthalmic Solutions Clinical Study Group. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children. Clin Ther. 2009;31:1908\u201321.","journal-title":"Clin Ther"},{"key":"155_CR26","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2147\/JAA.S38671","volume":"6","author":"S Ackerman","year":"2013","unstructured":"Ackerman S, D\u2019Ambrosio F Jr., Greiner JV, Villanueva L, Ciolino JB, Hollander DA. A multicenter evaluation of the efficacy and duration of action of alcaftadine 0.25% and olopatadine 0.2% in the conjunctival allergen challenge model. J Asthma Allergy. 2013;6:43\u201352.","journal-title":"J Asthma Allergy."},{"key":"155_CR27","doi-asserted-by":"crossref","unstructured":"McLaurin EB, Marsico NP, Ciolino JB, Williams JM, Hollander DA. Alcaftadine 0.25% versus olopatadine 0.2% in the prevention of ocular itching in allergic conjunctivitis. Presented at: American College of Allergy, Asthma and Immunology 2013 Annual Scientific Meeting; November 7\u201311, 2013; Baltimore, MD.","DOI":"10.1016\/j.jaci.2013.12.986"},{"key":"155_CR28","doi-asserted-by":"crossref","unstructured":"McLaurin EB, Marsico NP, Ciolino JB, Williams JM, Hollander DA. Alcaftadine 0.25% versus olopatadine 0.2% in prevention of ocular itching due to allergic conjunctivitis in a CAC\u2122 model. Presented at: American Academy of Ophthalmology 2013 Annual Meeting; November 16\u201319, 2013; New Orleans, LA.","DOI":"10.1016\/j.jaci.2013.12.986"},{"key":"155_CR29","unstructured":"Medical Dictionary for Regulatory Activities, MedDRA MSSO, McLean, VA. 2013. URL: http:\/\/www.meddra.org\/ . Accessed February 28, 2013."},{"key":"155_CR30","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1358\/dot.2011.47.12.1709243","volume":"47","author":"R Namdar","year":"2011","unstructured":"Namdar R, Valdez C. Alcaftadine: a topical antihistamine for use in allergic conjunctivitis. Drugs Today (Barc). 2011;47:883\u201390.","journal-title":"Drugs Today (Barc)."},{"key":"155_CR31","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/sj.bjp.0705729","volume":"142","author":"P Ling","year":"2004","unstructured":"Ling P, Ngo K, Nguyen S, Thurmond RL, Edwards JP, Karlsson L, et al. Histamine H4 receptor mediates eosinophil chemotaxis with cell shape change and adhesion molecule upregulation. Br J Pharmacol. 2004;142:161\u201371.","journal-title":"Br J Pharmacol"},{"key":"155_CR32","first-page":"77","volume":"5","author":"SJ Ono","year":"2011","unstructured":"Ono SJ, Lane K. Comparison of effects of alcaftadine and olopatadine on conjunctival epithelium and eosinophil recruitment in a murine model of allergic conjunctivitis. Drug Des Devel Ther. 2011;5:77\u201384.","journal-title":"Drug Des Devel Ther."},{"key":"155_CR33","doi-asserted-by":"crossref","first-page":"971","DOI":"10.3109\/02713683.2012.700756","volume":"37","author":"L Contreras-Ruiz","year":"2012","unstructured":"Contreras-Ruiz L, Schulze U, Garc\u00eda-Posadas L, Arranz-Valsero I, Lopez-Garcia A, Paulsen F, et al. Structural and functional alteration of corneal epithelial barrier under inflammatory conditions. Curr Eye Res. 2012;37:971\u201381.","journal-title":"Curr Eye Res"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-014-0155-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,15]],"date-time":"2019-08-15T08:04:52Z","timestamp":1565856292000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-014-0155-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,27]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["155"],"URL":"https:\/\/doi.org\/10.1007\/s12325-014-0155-3","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,27]]}}}